KRAS and neoplasm: Interestingly, classical cell lines were more sensitive to erlotinib while quasi-mesenchymal cells were more sensitive to gemcitabine, suggesting that, despite the almost ubiquitous KRAS mutation, EGFR may be more or less influent depending on the tumor molecular subtype and the whole pathway modulation should be considered, especially at its relevant “checkpoints”.